MedAvante and ProPhase pioneered ingenious solutions to some of pharma’s most intractable problems.

Both companies were founded more than a decade ago to address high failure rates of clinical trials of psychotropic drugs, the efficacy of which are measured with subjective ratings susceptible to biases, variability and error.

MedAvante pioneered Central Ratings, an unconventional solution built on the novel idea of having a small highly calibrated cohort of expert raters administer clinical outcome assessments remotely.

ProPhase became a global provider of measurement-related specialty solutions in clinical trials by focusing on optimizing the selection, use, and analysis of behavioral endpoints to mitigate trial risk and maximize the likelihood of study success.

As Central Ratings gained acceptance in large global studies, MedAvante replaced the paper-based rating scales its own clinicians were using by developing a digital platform to administer clinical outcome assessments (eCOA) and manage electronic source (eSource) data, starting in 2009.

Today’s generation of that technology innovation is the Virgil platform, used in clinical trials around the world to improve efficiency and quality at research sites while providing study sponsors with immediate access to high quality clinical trial data.

MedAvante-ProPhase is committed to continuing to bring digital innovation and scientific quality to the crucially important process of collecting, managing and analyzing clinical trial data. We will build on the great progress we’ve made improving signal detection in CNS studies to enable smarter, faster clinical trials in all therapeutic areas that will bring better treatments to the people who need them most.